Experimental drug combo tested for rare, deadly castleman disease
NCT ID NCT00092222
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the disease progresses over time. Participants will have extra blood draws and biopsies to help researchers learn more.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Etoposide, interferon-alpha, zidovudine, valganciclovir, bortezomib, rituximab, liposomal doxorubicin
What this could lead to
If successful, this study could improve understanding and treatment options for KSHV-MCD, a rare and deadly disease with no standard therapy.
What could go wrong
This is a small, early-phase study (75 participants) with multiple experimental drug combinations. Side effects can be severe, and there is no guarantee of direct benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.